Deerfield Management

Name

Deerfield Management

Legal name

Deerfield Management Company, L.P.

Website

https://deerfield.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Healthcare Investment Management

NAICS

Portfolio Management and Investment Advice (523940), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Investment Advice (6282), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Venture Capital Fund-of-Funds / Multi-Manager Platforms (FSANAAAJ)

Keywords

• Healthcare venture capital
• Life sciences investment
• Drug discovery services
• Biotech investment management
• Medical device investment

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

1. Private Investment Fund Management Fees & Carried Interest: Deerfield Private Design Fund V ($1.4B) and other fund vehicles (Healthcare Innovations Fund III, >$600M) generate revenue through management fees and carried interest on customized private and public investment solutions.
2. Investment Advisory Fees: Deerfield is registered under the Investment Advisers Act of 1940 and provides investment advisory services to a limited number of private investment vehicles, charging fees and other compensation disclosed in fund documents.
3. Portfolio Company Exits / Capital Gains: Realized returns from sale of portfolio companies (e.g., Melinta Therapeutics sold to CorMedix in September 2025; Nuvalent acquisition by GSK for $10.6B in 2026, generating over $200M for the Deerfield Foundation).

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels6 records

Core offering

Deerfield Management is a healthcare investment management firm that deploys capital and proprietary R&D infrastructure across the healthcare ecosystem. Its core offerings are organized into three pillars: Investment (multiple private funds including the $1.4B Private Design Fund V and $600M+ Healthcare Innovations Fund III, deployed into 40+ portfolio companies and 20+ academic joint ventures), Intelligence (AI/ML and market research applied to drug discovery via the 3DC R&D engine), and Philanthropy (Deerfield Foundation grants and XSeed Awards). The firm provides flexible funding, in-house drug discovery capabilities through 3DC, dedicated workspace at the Cure NYC innovation campus, and long-term strategic co-development partnerships with biopharma, academic medical centers, and healthcare payers.

Product overview

Deerfield Management operates a platform-plus-modules architecture for advancing healthcare through three integrated pillars: Investment, Intelligence, and Philanthropy. At the core is the 3DC (Deerfield Discovery and Development) R&D engine, which is the company's in-house drug discovery platform spanning small molecules and biologics, complemented by Deerfield Catalyst (a medtech incubator) and Cure (a healthcare innovation ecosystem at NYC headquarters housing state-of-the-art labs). The Investment pillar supports portfolio companies and built ventures including Neomorph (molecular glues), Nuvalent (precision oncology), Elion Therapeutics (antifungals), and physician enablement platforms Alo Solutions and Vanova Health; the Intelligence pillar applies AI, data, and market research; and the Philanthropy pillar operates the Deerfield Foundation (including the XSeed Award program) and is supported by strategic collaborations with over 20 academic research institutions.

Differentiator

Problem solved

Functional benefit

Brands

• Deerfield Discovery and Development (3DC): Deerfield's in-house company-building R&D engine that advances early-stage therapeutics from scientific discovery through preclinical proof of concept and into the clinic.
• Genscience
• Deerfield Catalyst
• Cure
• Deerfield Foundation

Products and services

• Deerfield Discovery and Development (3DC) Deerfield's internal research and development engine and company-building R&D platform providing translational biology, drug metabolism and pharmacokinetics, chemistry/CMC, data science, biologics, cell and gene therapy, clinical/regulatory, and project management capabilities for portfolio companies, academic collaborators, and biopharma partners.
• Cure Healthcare Innovation Ecosystem A premier healthcare innovation ecosystem headquartered at 345 Park Avenue South in New York City, housing numerous life science and healthcare companies with in-building laboratory facilities, state-of-the-art equipment, and digital community serving health innovators.
• Deerfield Investment Services (Private Design Fund V and Healthcare Innovations Fund III) Private investment fund management providing flexible funding models to companies across the healthcare ecosystem via multiple fund vehicles including Healthcare Innovations Fund III (over $600M) and Private Design Fund V ($1.4B). Available to private and public companies at all stages of innovation.
• Deerfield Intelligence AI, data, and market research platform driving healthcare technology and innovation forward, integrated across investment, intelligence, and philanthropy functions. Includes Artificial Intelligence and Machine Learning capabilities plus Market Research offerings.
• Deerfield Foundation Not-for-profit philanthropic arm based in New York City that advances innovative healthcare initiatives, awards grants to improve health and accelerate innovation (including $1.5M and $1.4M grant cycles to organizations across seven countries focused on children's health), supports AML research via the ASH Peter Steelman Scholar Award, and operates the XSeed Award program.
• Deerfield Catalyst (Medtech Incubator) Medtech incubator housed at Cure in New York City, committed to developing transformational solutions to improve patient outcomes and streamline care through medical technology incubation.
• Alo Solutions Healthcare services platform built by Deerfield in partnership with Blue Cross Blue Shield of North Carolina that enables independent physicians in North Carolina to manage the business of medicine through physician enablement capabilities.
• Vanova Health Healthcare services platform built by Deerfield with Blue Cross Blue Shield of New Jersey to provide essential tools and services that support independent physician practices; launched as a joint venture.
• Strategic Partnerships Program Bespoke industrial partnership program offering capital, scientific expertise, business and operational support, and access to innovation across the healthcare ecosystem for large biopharma and life-sciences tools companies (J&J Innovation, Lilly, Pfizer, Thermo Fisher, Illumina, Insilico Medicine, Charles River Laboratories, Schrödinger, Relation Therapeutics, BioSymetrics).
• Cure by Deerfield Middle East Health Accelerator 12-week hybrid accelerator program for healthcare startups operating in the Middle East (Doha, Qatar) with mentorship, investor access, and pilot project opportunities, operating alongside the Qatar Investment Authority Fund of Funds VC program and Deerfield's regional office in Doha.
• Genscience Genetics Platform Affiliate genetics platform providing genetic evidence to aid discovery of more effective drug targets; published in Nature on the positive impact of genetic evidence on target discovery.
• Lab of the Future Next-generation AI/ML-enabled laboratory at the Cure NYC healthcare innovation campus funded by a $25 million New York State/Empire State Development grant, leveraging artificial intelligence and machine learning to drastically improve the speed, accuracy, and cost of drug development.

Quantifiable outcome

• $10.6B acquisition of portfolio company Nuvalent by GSK (2026)
• +5 more outcomes

Named customers12 records

Segments6 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature5 records

Partnerships

40 partnerships are on record, tiered past portfolio company (exited), flagship healthcare services partner, flagship clinical partner, strategic partner, flagship biopharma partner, major biopharma partner, partner, flagship academic partner, flagship international academic partner and portfolio company.

• Melinta Therapeuticspast portfolio company (exited)Strategic or Co-development PartnerDeerfield acquired Melinta Therapeutics in 2020, growing revenue and product portfolio through leadership and acquisitions, then sold it to CorMedix, Inc. in September 2025. Illustrates Deerfield's integrated financial + operational value creation.
• Blue Cross Blue Shield of North Carolinaflagship healthcare services partnerStrategic or Co-development PartnerDeerfield partnered with BCBS North Carolina to build Alo Solutions, a physician enablement platform supporting independent North Carolina physicians managing the business of medicine.
• Horizon Blue Cross Blue Shield of New Jerseyflagship healthcare services partnerStrategic or Co-development PartnerJoint venture to support and sustain independent physicians in New Jersey; partnership underlies the Vanova Health platform.
• Hospital for Special Surgery (HSS)flagship clinical partnerStrategic or Co-development PartnerAlliance for Innovation in Movement (AIM) launched November 13, 2025 to combine HSS clinical expertise with Deerfield capital, infrastructure, and scientific expertise to develop medical devices, therapeutics, AI-powered digital tools, and consumer technologies for musculoskeletal health and longevity.
• Metis TechBiostrategic partnerStrategic or Co-development PartnerMetis TechBio entered a strategic alliance with Deerfield (announced May 28, 2026) to advance AI-driven protein therapeutics and in vivo immunotherapy.
• Johnson & Johnson Innovationflagship biopharma partnerStrategic or Co-development PartnerSelect industrial partnership; potential acquisition of projects in areas of partner's interest with access to high-quality and later-stage projects plus industrial-scale resources.
• Eli Lillyflagship biopharma partnerStrategic or Co-development PartnerIndustrial partnership; potential access to proprietary novel platforms and ability to "buy in bulk" for multiple projects at one time. Lilly also participates in select Deerfield portfolio deals (e.g., Excelsior Sciences Series A).
• Pfizermajor biopharma partnerStrategic or Co-development PartnerIndustrial collaboration partner in Deerfield's select industrial partnerships program.
• Thermo Fisher Scientificmajor biopharma partnerStrategic or Co-development PartnerIndustrial collaboration partner in Deerfield's select industrial partnerships program.
• Illuminamajor biopharma partnerStrategic or Co-development PartnerIndustrial collaboration partner; also a first-of-its-kind partnership to identify drug targets and accelerate novel therapy development using genomics and artificial intelligence (announced May 5, 2022).
• BioSymetricspartnerStrategic or Co-development PartnerIndustrial partnership plus research collaboration (October 31, 2022) using phenomics and genomic data to advance cardiology and neurology targets.
• Relation TherapeuticspartnerStrategic or Co-development PartnerIndustrial collaboration partner in Deerfield's select industrial partnerships program.
• Insilico MedicinepartnerStrategic or Co-development PartnerIndustrial partnership; access to AI-driven drug discovery and proprietary novel platforms.
• Charles River LaboratoriespartnerStrategic or Co-development PartnerIndustrial partnership providing access to expanded marginal workforce and seasoned drug-development experts.
• SchrödingerpartnerStrategic or Co-development PartnerIndustrial partnership; access to proprietary computational chemistry platforms.
• Harvard University (Lab1636)flagship academic partnerStrategic or Co-development PartnerMajor strategic R&D alliance announced March 2019 to speed the development and translation of biomedical and life-science innovations into transformative treatments.
• NYU Langone Health (Amethyst Innovations)flagship academic partnerStrategic or Co-development PartnerR&D collaboration launched June 2023 with up to $130M committed by Deerfield to accelerate commercialization of biomedical discoveries.
• Moffitt Cancer Center (Bayfield Therapeutics)flagship academic partnerStrategic or Co-development PartnerTranslational research alliance launched September 2022 with up to $130M committed over 10 years by Deerfield to accelerate cancer therapeutic development.
• Washington University in St. Louis (VeritaScience)flagship academic partnerStrategic or Co-development PartnerR&D collaboration launched January 2024 with up to $130M committed by Deerfield over a 10-year commitment to advance therapeutic and diagnostic candidates.
• Dana-Farber Cancer Institute (Riverway Discoveries)flagship academic partnerStrategic or Co-development PartnerMajor translational research partnership launched February 2021 with up to $130M committed over 10 years to accelerate cancer therapeutics and diagnostics. Underpins Neomorph and other initiatives.
• University of North Carolina at Chapel Hill (Pinnacle Hill)flagship academic partnerStrategic or Co-development PartnerDeerfield-UNC launch announced October 2018 to discover new medicines addressing unmet medical needs. Includes the UNC Eshelman School of Pharmacy "Molecules to Market" Biotherapeutics Certificate Program.
• Yeda / Weizmann Institute of Science (Orchard Innovations)flagship international academic partnerStrategic or Co-development PartnerExtensive translational research initiative announced January 2019 — Deerfield's first collaboration outside the USA — to catalyze transformative treatments toward clinical validation.
• Northwestern University (Lakeside Discovery)flagship academic partnerStrategic or Co-development PartnerLaunched May 2018 to accelerate translation of transformative biomedical technologies with up to $65M of targeted funding from Deerfield.
• University of Chicago (Hyde Park Discovery)flagship academic partnerStrategic or Co-development PartnerCollaboration launched January 2025 with up to $130M committed by Deerfield to accelerate translation of research into life-saving treatments.
• Columbia University (Hudson Heights Innovations)flagship academic partnerStrategic or Co-development PartnerMajor R&D alliance announced June 2019 to advance the translation of biomedical discoveries into transformative treatments.
• Cold Spring Harbor Laboratory (Harbor Discoveries)flagship academic partnerStrategic or Co-development PartnerR&D collaboration announced January 2023 with up to $130M committed over 10 years by Deerfield to advance next-generation therapeutics.
• University of Michigan (Great Lakes Discovery)flagship academic partnerStrategic or Co-development PartnerPartnership announced May 2020 with up to $130M committed by Deerfield to commercialize therapeutic projects.
• Duke University (Four Points Innovation)flagship academic partnerStrategic or Co-development PartnerMajor research collaboration announced December 2019 to accelerate the preclinical development of new drugs for improved quality of life and cures for diseases.
• Beth Israel Deaconess Medical Center (Brookline Avenue Innovations)flagship academic partnerStrategic or Co-development PartnerResearch collaboration announced September 2022 with up to $130M committed by Deerfield to translate BIDMC research programs from bench to bedside.
• Broad Institute of MIT and Harvardflagship academic partnerStrategic or Co-development PartnerPartnership launched October 2017 to tackle serious unmet medical needs; Broad is a highly integrated biomedical and genomic research center with more than 3,000 scientists.
• Baylor College of Medicine (Blue Square Discoveries)flagship academic partnerStrategic or Co-development PartnerMajor research collaboration announced May 2021 with up to $130M committed by Deerfield to advance promising therapeutics.
• Johns Hopkins University (Bluefield Innovations)flagship academic partnerStrategic or Co-development PartnerCollaboration launched October 2017 to catalyze the development of early-stage therapeutics.
• Boston Children's Hospital (Blackfan Circle Innovations)flagship academic partnerStrategic or Co-development PartnerMajor research collaboration announced November 2020 — first Deerfield collaboration with a pediatric research hospital — to advance novel pediatric therapies.
• Vanderbilt University (Ancora Innovation)flagship academic partnerStrategic or Co-development PartnerLaunched April 2018 to support Vanderbilt's innovative life science research and leverage Deerfield's drug development expertise.
• Stanford University (Porter Alliance for Innovative Medicines)flagship academic partnerStrategic or Co-development PartnerCollaboration announced January 2022 with up to $130M committed by Deerfield to support Stanford's innovative translational research.
• University of Illinois at Chicago (West Loop Innovations)partnerStrategic or Co-development PartnerEstablished April 2019 to accelerate the commercialization of therapeutics developed at UIC.
• Empire Discovery Institute (Empire-Deerfield Discovery & Development / ED3)partnerStrategic or Co-development PartnerLaunched April 2021 with up to $65M committed by Deerfield over five years to fund translational research.
• Invitaestrategic partnerStrategic or Co-development PartnerPartnership announced March 22, 2023 to harness genetic and clinical data from millions of patients tested at Invitae and Deerfield's drug discovery expertise to create novel therapeutics for rare diseases.
• myLaurelportfolio companyStrategic or Co-development PartnerDeerfield-affiliated investment ecosystem partner; myLaurel provides technology-enabled, hospital-aligned home care with reported 400% partner increase and 575% surge in patients served in 2025.
• DocereepartnerGTM or Marketing PartnerDeerfield represented among 18 senior agency leaders co-building Daily Command, Doceree's AI-powered operating system for healthcare marketing, which launched May 7, 2026.

Scale indicators8 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• ARCH Venture Partners: ARCH is a long-standing venture capital firm that combines large dedicated life-sciences funds with deep academic medical-center partnerships (e.g., University of Chicago, University of Washington) and in-house science capabilities. Most directly comparable to Deerfield on the integrated capital + academic + in-house R&D model.
• Third Rock Ventures: Third Rock conceives, launches, and operates biotech companies from inception, providing founding teams, R&D infrastructure, and capital — closely mirroring Deerfield's 3DC and Cure-driven company-building motion and its preference for forming companies around academic science.
• Frazier Healthcare Partners: Frazier is a dedicated healthcare investment firm with both growth and life-sciences strategies; comparable to Deerfield on multi-stage healthcare investing and operating company creation (e.g., selling mature portfolio assets to strategic acquirers).
• Versant Ventures: Versant is a healthcare-focused venture firm that both invests in and in-licenses early-stage therapeutics, comparable to Deerfield on the build / co-build approach to biotech creation and on heavy emphasis on therapeutic venture.
• Flagship Pioneering: Flagship builds biotech companies from internal hypotheses and provides both capital and in-house scientific platforms (e.g., the ProFoundry, Generate Biomedicines). Closely comparable to Deerfield on the 'build with the firm' model and on combining generalist VC capital with deep internal R&D infrastructure.
• Polaris Partners: Polaris is a multi-stage venture firm with a strong life-sciences practice that co-founds biotech companies. Comparable to Deerfield on company-building motion and on blending venture capital with operating involvement.
• OrbiMed: OrbiMed is a healthcare-dedicated investment firm across private equity, venture, and public equity. Directly comparable to Deerfield on dedicated healthcare focus, multi-stage fund structure, and broad therapeutic coverage including devices, diagnostics, and therapeutics.
• Venrock: Venrock is a long-tenured venture firm with deep healthcare and biotech expertise (e.g., co-founded several disease-area companies). Comparable to Deerfield on dedicated healthcare practice and on leveraging institutional academic networks for deal flow.
• Atlas Venture: Atlas is a Boston-based early-stage life-sciences VC that builds and seeds biotech companies — comparable to Deerfield on its focus on forming companies around academic science and its therapeutics-only mandate.

Broad incumbents

• New Enterprise Associates (NEA): NEA is a large, multi-stage venture firm with a substantial dedicated healthcare practice. Comparable to Deerfield on scale and multi-stage healthcare deployment, though NEA operates as a broad tech-and-healthcare investor rather than a healthcare-pure-play.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/deerfield-management

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries35 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments44 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Deerfield Management